A review on antibiotics induced nephrotoxicity
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20231899Keywords:
Acute kidney injury, Chronic kidney disease, Antibiotics, NephrotoxicityAbstract
One of the common causes of acute kidney injury (AKI) is drug nephrotoxicity. AKIs around 20-60% in hospitalised patients are caused by drug-induced nephrotoxicity, which is also linked to higher morbidity and death both in children and adults. Antibiotics are one of the most frequently prescribed drug classes worldwide and, also one of the leading contributors to nephrotoxicity. Nephrotoxicity has been related to a wide range of antimicrobial medications, although the characteristics of kidney damage vary depending on the agent, the site of toxicity and the mechanism of injury within the renal. Acute tubular necrosis, acute interstitial nephritis, crystal nephropathy, and proximal/distal tubulopathy with electrolyte problems are the most frequent mechanisms. Pre-existing chronic renal disease and concurrent use of medications with nephrotoxic potential are two general risk factors for antimicrobial-induced AKI. The various types of antimicrobial-induced nephrotoxicity especially antibiotics will be discussed in this review and offer guidance on how to prevent AKI and recognize it early in order to reduce it and prevent morbidity.
References
Schetz M, Dasta J, Goldstein S, Golper T. Drug-induced acute kidney injury. Curr Opin Crit Care. 2005;11(6):555-65.
Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med. 1996;334(22):1448-60.
Stavreva G, Pendicheva D, Pandurska A, Marev R. Detection of adverse drug reactions to antimicrobial drugs in hospitalized patients. Trakia J Sci. 2008;6(1):7-9.
Wawruch M, Bozekova L, Krcmery S, Kriska M. Risks of antibiotic treatment. Bratislavske lekarske listy. 2002;103(7/8):270-5.
Rouveix B. Antibiotic safety assessment. Int J Antimicrob Agents. 2003;21(3):215-21.
Baykal A, Sarigül F, Süleymanlar G, Moreira PI, Perry G, Smith MA, Alicigüzel Y. Ciprofloxacin does not exert nephrotoxicity in rats. Am J Infect Dis. 2005;1(3):145-8.
Nolin TD. Drug-Induced Kidney Disease. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L, editors. Pharmacotherapy: A Pathophysiologic Approach, 10e. McGraw Hill. 2017.
Devasmita C, Ziauddin A. Drug-associated renal dysfunction and injury. Nat Clin Pract Nephrol. 2006;2(2):80-91.
Streetman DS, Nafziger AN, Destache CJ, Bertino Jr JS. Individualized pharmacokinetic monitoring results in less aminoglycoside‐associated nephrotoxicity and fewer associated costs. Pharmacotherapy. 2001;21(4):443-51.
Slaughter RL, Cappelletty DM. Economic impact of aminoglycoside toxicity and its prevention through therapeutic drug monitoring. Pharmacoeconomics. 1998;14(4):385-94.
Martinez-Salgado C, López-Hernández FJ, López-Novoa JM. Glomerular nephrotoxicity of aminoglycosides. Toxicol Appl Pharmacol. 2007;223(1):86-98.
Naughton CA. Drug-induced nephrotoxicity. Am Fam Phys. 2008;78(6):743-50.
Perazella MA. Drug-induced nephropathy: an update. Exp Opin Drug Safety. 2005;4(4):689-706.
Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med. 2002;347(16):1256-61.
Olyaei AJ, De Mattos AM, Bennett DW. Immunosuppressant-induced nephropathy. Drug Safety. 1999;21(6):471-88.
Markowitz GS, Perazella MA. Drug-induced renal failure: a focus on tubulointerstitial disease. Clinica Chimica Acta. 2005;351(1-2):31-47.
Perazella MA. Drug-induced nephropathy: an update. Expert Opin Drug Saf. 2005;4(4):689-706.
Rossert J. Drug-induced acute interstitial nephritis. Kidney Int. 2001;60(2):804-17.
Markowitz GS, Perazella MA. Drug-induced renal failure: a focus on tubulointerstitial disease. Clin Chim Acta. 2005;351(1-2):31-47.
Moore RD, Smith CR, Lipsky JJ, Mellits ED, Lietman PS. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Int Med. 1984;100(3):352-7.
Nagai J, Takano M. Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab Pharmacokinetics. 2004;19(3):159-70.
Morales-Alvarez MC. Nephrotoxicity of antimicrobials and antibiotics. Adv Chronic Kidney Dis. 2020;27(1):31-7.
Tune BM. Nephrotoxicity of beta-lactam antibiotics: mechanisms and strategies for prevention. Pediatric Nephrol. 1997;11(6):768-72.
Linder JA, Huang ES, Steinman MA. Fluoroquinolone prescribing in the United States: 1995–2002. Am J Med. 2005;118:259-68.
Ciprofloxacin. Schaumberg, IL: SAGENT Pharmaceuticals. 2011. Available at: https://www. sagentpharma.com/wpcproduct/ciprofloxacin-injection-usp-2/. Accessed on 12 February 2023.
Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366:1881-90.
Lien YH, Hansen R, Kern WF, Bangert J, Nagle RB, Ko M, et al. Ciprofloxacin-induced granulomatous interstitial nephritis and localized elastolysis. Am J Kidney Dis. 1993;22:598-602.
Ramalakshmi S, Bastacky S, Johnson JP. Levofloxacin-induced granulomatour interstitial nephritis. Am J Kidney Dis. 2003;41:E7.
Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R. Crystalluria and ciprofloxacin, influence of urinary pH and hydration. Chemotherapy. 1986;32:408-17.
Harel Z, Gilbert C, Wald R, Bell C, Perl J, Juurlink D, et al. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalemia and AKI: systematic review and metaanalysis. BMJ. 2012;9:344:e42.
Bird ST, Etminan M, Brophy JM, Hartzema AG, Delaney JA. Risk of acute kidney injury associated with the use of fluoroquinolones. CMAJ. 2013;185(10):E475-82.
Kastrup J, Petersen P, Bartram R, Hansen JM. The effect of trimethoprim on serum creatinine. Br J Urol. 1985;57(3):265-8.
Roy MT, First MR, Myre SA, Cacini W. Effect of co-trimoxazole and sulfamethoxazole on serum creatinine in normal subjects. Ther Drug Monit. 1982;4(1):77-9.
Alappan R, Perazella MA, Buller GK. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Intern Med. 1996;124(3):316-20.
Perazella MA, Mahnensmith RL. Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose. Clin Nephrol. 1996;46(3):187-92.
Jick H, Derby LE. A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and cephalexin for uncommon serious drug toxicity. Pharmacotherapy. 1995;15(4):428-32.
Fraser TN, Avellaneda AA, Graviss EA, Musher DM. Acute kidney injury associated with trimethoprim/sulfamethoxazole. J Antimicrob Chemother. 2012;67(5):1271-7.
Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE. Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases. Clinical Nephrol. 1993;39(5):254-6.
Simon DI, Brosius FC 3rd, Rothstein DM. Sulfadiazine crystalluria revisited. The treatment of Toxoplasma encephalitis in patients with acquired immunodeficiency syndrome. Arch Intern Med. 1990;150(11): 2379-84.
Sinha Ray A, Haikal A, Hammoud KA, Yu AS. Vancomycin and the risk of AKI: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2016;11(12):2132-40.
Cosgrove SE, Vigliani GA, Fowler VG Jr. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis. 2009;48(6):713-21.
Morales-Alvarez MC. Nephrotoxicity of Antimicrobials and Antibiotics. Adv Chronic Kidney Dis. 2020;27(1):31-7.
Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents. 2005;25(1):11-25.
Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis. 2009;22(6):535-43.
Kim J, Lee KH, Yoo S, Pai H. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents. 2009;34(5):434-8.
Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honore PM. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care. 2011;1(1):14.
Vardakas KZ, Falagas ME. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis. Int J Antimicrob Agents. 2017;49(2):233-8.
Vaamonde CA. Risk factors in nephrotoxicity. Homeostasis, Nephrotoxicity, and Renal Anomalies in the Newborn. 1986:49-85.
Schetz M, Dasta J, Goldstein S, Golper T. Drug-induced acute kidney injury. Curr Opin Crit Care. 2005;11(6):555-65.
Leblanc M, Kellum JA, Gibney RT, Lieberthal W, Tumlin J, Mehta R. Risk factors for acute renal failure: inherent and modifiable risks. Curr Opin Crit Care. 2005;11(6):533-6.
Perazella MA. Crystal-induced acute renal failure. Am J Med. 1999;106(4):459-65.
Barrett BJ, Parfrey PS. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med. 2006;354(4):379-86.
McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F, et al. Risk prediction of contrast-induced nephropathy. Am J Cardiol. 2006;98(6A):27K-36K.
Briguori C, Airoldi F, D'Andrea D, Bonizzoni E, Morici N, Focaccio A, et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation. 2007;115(10):1211-7.
Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med. 2002;347(16):1256-61.
Guo X, Nzerue C. How to prevent, recognize, and treat drug-induced nephrotoxicity. Cleve Clin J Med. 2002;69(4):289-312.
Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139(2):137-47.
